Skip to main content
Top

18-08-2018 | Continuous glucose monitoring | Review | Article

Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology

Journal: Current Diabetes Reports

Authors: Paola Lucidi, Francesca Porcellati, Geremia B. Bolli, Carmine G. Fanelli

Publisher: Springer US

Abstract

Purpose of Review

In addition to assisting in achieving improved glucose control, continuous glucose monitoring (CGM) sensor technology may also aid in detection and prevention of hypoglycemia. In this paper, we report on the current scientific evidence on the effectiveness of this technology in the prevention of severe hypoglycemia and hypoglycemia unawareness.

Recent Findings

Recent studies have found that the integration of CGM with continuous subcutaneous insulin infusion (CSII) therapy, a system known as sensor-augmented pump (SAP) therapy, very significantly reduces the occurrence of these conditions by providing real-time glucose readings/trends and automatically suspending insulin infusion when glucose is low (LGS) or, even, before glucose is low but is predicted to soon be low (PLGS). Initial data indicate that even for patients with type 1 diabetes treated with multiple daily injections, real-time CGM alone has been found to reduce both severe hypoglycemia and hypoglycemia unawareness. Closed loop systems (artificial pancreas) comprised of CGM and CSII without patient intervention to adjust basal insulin, which automatically reduce, increase, and suspend insulin delivery, represent a potential new option that is moving toward becoming a reality in the near future.

Summary

Sensor technology promises to continue to improve patients’ lives not only by attaining glycemic control but also by reducing hypoglycemia, a goal best achieved in conjunction with structured individualized patient education.
Literature
1.
Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28:1245–9.CrossRef
2.
Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384–95.CrossRefPubMedPubMedCentral
3.
International Hypoglycemia Study Group. Glucose concentrations of less than 3.0 mmol/L [54 mg/dL] should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2017;40:155–7.CrossRef
4.
Johnston SS, Conner C, Aagren M, Smith DM, Bouchard J, Brett J. Evidence linking hypoglycemic events to an increased risk of acute cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2011;34:1164–70.CrossRefPubMedPubMedCentral
5.
Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. Diabetes Care. 2010;33:1389–94.CrossRefPubMedPubMedCentral
6.
Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA. 2009;301:1565–72.CrossRefPubMedPubMedCentral
7.
Johnston SS, Conner C, Aagren M, Ruiz K, Bouchard J. Association between hypoglycemic events and fall-related fractures in medicare-covered patients with type 2 diabetes. Diabetes Obes Metab. 2012;14:634–43.CrossRefPubMed
8.
McCoy RG, Van Houten HK, Ziegenfuss JY, Shah ND, Wermers RA, Smith SA. Increased mortality of patients with diabetes reporting severe hypoglycemia. Diabetes Care. 2012;35:1897–901.CrossRefPubMedPubMedCentral
9.
Green AJ, Fox KM, Grandy S, SHIELD Study Group. Self-reported hypoglycemia and impact on quality of life and depression among adults with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2012;96:313–8.CrossRefPubMed
10.
Laiteerapong N, Karter AJ, Liu JY, Moffet HH, Sudore R, Schillinger D, et al. Correlates of quality of life in older adults with diabetes: the diabetes & aging study. Diabetes Care. 2011;34:1749–53.CrossRefPubMedPubMedCentral
11.
Leiter LA, Yale J-F, Chiasson JL, Harris S, Kleinstiver P, Sauriol L. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes. 2005;29:186–92.
12.
Kilpatrick ES, Rigby AS, Goode K, Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia. 2007;50:2553–61.CrossRefPubMed
13.
Rama Chandran S, Tay WL, Lye WK, Lim LL, Ratnasingam J, Tan ATB, et al. Beyond HbA1c: comparing glycemic variability and glycemic indices in predicting hypoglycemia in type 1 and type 2 diabetes. Diabetes Technol Ther. 2018;20:353–62.CrossRefPubMed
14.
Bolli GB, Dimitriadis GD, Pehling GB, Baker BA, Haymond MW, Cryer PE, et al. Abnormal glucose counterregulation after subcutaneous insulin in insulin-dependent diabetes mellitus. N Engl J Med. 1984;310:1706–11.CrossRefPubMed
15.
Arbelaez AM, Xing D, Cryer PE, Kollman C, Beck RW, Sherr J, et al. Blunted glucagon but not epinephrine responses to hypoglycemia occurs in youth with less than 1 yr duration of type 1 diabetes mellitus. Pediatr Diabetes. 2014;15:127–34.CrossRefPubMed
16.
Cryer PE. Mechanisms of hypoglycemia-associated autonomic failure in diabetes. N Engl J Med. 2013;369:362–72.CrossRefPubMed
17.
Fanelli C, Epifano L, Rambotti A, Pampanelli S, Di Vincenzo A, Modarelli F, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes. 1993;42:1683–9.CrossRefPubMed
18.
Fanelli C, Pampanelli S, Lalli C, Del Sindaco P, Ciofetta M, Lepore M, et al. Long-term intensive therapy of IDDM diabetic patients with clinically overt autonomic neuropathy: effects on awareness of, and counterregulation to hypoglycemia. Diabetes. 1997;46:1172–81.CrossRefPubMed
19.
White NH, Skor DA, Cryer PE, Levandoski LA, Bier DM, Santiago JV. Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med. 1983;308:485–91.CrossRefPubMed
20.
Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes. 2002;51:724–33.CrossRefPubMed
21.
UK Hypoglycemia Study Group. Risk of hypoglycemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007;50:1140–7.CrossRef
22.
Pedersen-Bjergaard U, Pramming S, Heller SR, Wallace TM, Rasmussen AK, Jørgensen HV, et al. Severe hypoglycemia in 1076 adult patients with type 1 diabetes: influence of risk markers and selection. Diabetes Metab Res Rev. 2004;20:479–86.CrossRefPubMed
23.
DCCT research group. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med. 1991;90:450–9.CrossRef
24.
Giorda CB, Ozzello A, Gentile S, Aglialoro A, Chiambretti A, Baccetti F, et al. Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes. Results of the HYPOS-1 study. Acta Diabetol. 2015;52:845–53.CrossRefPubMed
25.
Cryer PE. Hypoglycemia in diabetes: pathophysiology, prevalence, and prevention. 3rd ed. Alexandria: American Diabetes Association; 2016. p. 3–8.
26.
Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23:B21–9.PubMed
27.
Abraira C, Henderson W, Colwell J, et al. VA CSDM group. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes [VA feasibility study]. Diabetes Care. 1998;21:574–9.CrossRefPubMed
28.
The UKPDS Research Group. Overview of 6 years of therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249–58.CrossRef
29.
Giorda CB, Ozzello A, Gentile S, Corsi A, Iannarelli R, Baccetti F, et al. Incidence and correlates of hypoglycemia in type 2 diabetes. The Hypos-1 study. J Diabetes Metab. 2014;3:2.
30.
Gerich JE, Mokan M, Veneman T, Korytkowski M, Mitrakou A. Hypoglycemia unawareness. Endocr Rev. 1991;12:356–71.CrossRefPubMed
31.
Geddes J, Schopman JE, Zammitt NN, Frier BM. Prevalence of impaired awareness of hypoglycemia in adults with type 1 diabetes. Diabet Med. 2008;25:501–4.CrossRefPubMed
32.
Olsen SE, Asvold BO, Frier BM, Aune SE, Hansen LI, Bjørgaas MR. Hypoglycemia symptoms and impaired awareness of hypoglycemia in adults with type 1 diabetes: the association with diabetes duration. Diabet Med. 2014;31:1210–7.CrossRefPubMed
33.
Henderson JN, Allen KV, Deary IJ, Frier BM. Hypoglycemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med. 2003;20:1016–21.CrossRefPubMed
34.
Seaquist ER, Miller ME, Bonds DE, Feinglos M, Goff DC Jr, Peterson K, et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care. 2012;35:409–14.CrossRefPubMedPubMedCentral
35.
Lawrence RD. Insulin hypoglycaemia: changes in nervous manifestations. Lancet. 1941;238(6168):602.CrossRef
36.
Cryer PE. Hypoglycemia in diabetes: pathophysiology, prevalence, and prevention. 3rd ed. Alexandria: American Diabetes Association; 2016. p. 76–109.
37.
• Dagogo-Jack S. Philip E. Cryer, MD: seminal contributions to the understanding of hypoglycemia and glucose counterregulation and the discovery of HAAF (Cryer syndrome). Diabetes Care. 2015;38:2193–9. A good review of HAAF and its role in the development of severe hypoglycemia. CrossRefPubMedPubMedCentral
38.
Dagogo-Jack SE, Cryer PE. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest. 1993;91:819–8.CrossRefPubMedPubMedCentral
39.
Cox D, Gonder-Frederick L, Polonsky W, Schlundt D, Julian D, Clarke W. A multicenter evaluation of blood glucose awareness training-II. Diabetes Care. 1995;18:523–8.CrossRefPubMed
40.
Cox DJ, Gonder-Frederick L, Julian DM, Clarke W. Long-term follow-up evaluation of blood glucose awareness training. Diabetes Care. 1994;17:1–5.CrossRefPubMed
41.
Hopkins D, Lawrence I, Mansell P, Thompson G, Amiel S, Campbell M, et al. Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience. Diabetes Care. 2012;35:1638–42.CrossRefPubMedPubMedCentral
42.
de Zoysa N, Rogers H, Stadler M, Gianfrancesco C, Beveridge S, Britneff E, et al. A psychoeducational program to restore hypoglycemia awareness: the DAFNE-HART pilot study. Diabetes Care. 2014;37:863–6.CrossRefPubMed
43.
Rossetti P, Porcellati F, Bolli GB, Fanelli CG. Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes. Diabetes Care. 2008;31(Suppl 2):S113–20.CrossRefPubMed
44.
Bolli GB, Porcellati F, Lucidi P, Fanelli CG. Glucose control in diabetes: targets and therapy. In: Bruttomesso D, Grassi G, editors. Technological Advances in the Treatment of Type 1 Diabetes, Frontiers in diabetes, vol. 24; 2015. p. 1–10.
45.
• Lane W, Bailey TS, Gerety G, Gumprecht J, Philis-Tsimikas A, Hansen CT, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 1 diabetes: the SWITCH 1 randomized clinical trial. JAMA. 2017;318:33–44. A trial examining the risk of hypoglycemia with insulin degludec vs glargine U100 in T1DM subjects at high risk for severe hypoglycemia. CrossRefPubMedPubMedCentral
46.
Wysham C, Bhargava A, Chaykin L, de la Rosa R, Handelsman Y, Troelsen LN, et al. Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial. JAMA. 2017;318:45–56.CrossRefPubMedPubMedCentral
47.
Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with yype 1 diabetes: a randomized, phase 3a, open-label clinical trial [EDITION 4]. Diabetes Care. 2015;38:2217–25.CrossRefPubMed
48.
Home PD, Bergenstal RM, Bolli GB, Ziemen M, Rojeski M, Espinasse M, et al. Glycaemic control and hypoglycaemia during 12 months of randomized treatment with insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 1 diabetes [EDITION 4]. Diabetes Obes Metab. 2018;20:121–8.CrossRefPubMed
49.
Ritzel R, Roussel R, Bolli GB, Vinet L, Brulle-Wohlhueter C, Glezer S, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17:859–67.CrossRefPubMedPubMedCentral
50.
The American Diabetes Association. Glycemic targets: Standards of medical care in diabetes. Diabetes Care. 2018;41(suppl. 1):S55–64.CrossRef
51.
Pickup JC, Reznik Y, Sutton AJ. Glycemic control during continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 2 diabetes: individual patient data meta-analysis and meta-regression of randomized controlled trials. Diabetes Care. 2017;40:715–22.CrossRefPubMed
52.
Benkhadra K, Alahdab F, Tamhane SU, McCoy RG, Prokop LJ, Murad MH. Continuous subcutaneous insulin infusion versus multiple daily injections in individuals with type 1 diabetes: a systematic review and meta-analysis. Endocrine. 2017;55:77–84.CrossRefPubMed
53.
Monami M, Dicembrini I, Kundisova L, Zannoni S, Nreu B, Mannucci E. A meta-analysis of the hypoglycaemic risk in randomized controlled trials with sulphonylureas in patients with type 2 diabetes. Diabetes Obes Metab. 2014;16:833–40.CrossRefPubMed
54.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRef
55.
Miller KM, Beck RW, Bergenstal RM, Goland RS, Haller MJ, McGill JB, et al. Evidence of a strong association between frequency of self-monitoring of blood glucose and hemoglobin A1c levels in T1D exchange clinic registry participants. Diabetes Care. 2013;36:2009–14.CrossRefPubMedPubMedCentral
56.
• Cappon G, Acciaroli G, Vettoretti M, Facchinetti A, Sparacino G. Wearable continuous glucose monitoring sensors: a revolution in diabetes treatment. Electronics. 2017;6(3):65. This article presents a thorough overview of CGM sensor technologies. CrossRef
57.
Petrie JR, Peters AL, Bergenstal RM, Holl RW, Fleming GA, Heinemann L. Improving the clinical value and utility of CGM systems: issues and recommendations: a joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. Diabetes Care. 2017;40:1614–21.CrossRefPubMed
58.
Choudhary P, Shin J, Wang Y, Evans ML, Hammond PJ, Kerr D, et al. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care. 2011;34:2023–5.CrossRefPubMedPubMedCentral
59.
Bergenstal RM, Klonoff DC, Garg SK, Bode BW, Meredith M, Slover RH, et al. ASPIRE in-home study group threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013;369:224–32.CrossRefPubMed
60.
Buckingham B, Chase HP, Dassau E, Cobry E, Clinton P, Gage V, et al. Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Care. 2010;33:1013–7.CrossRefPubMedPubMedCentral
61.
• Zhong A, Choudhary P, McMahon C, Agrawal P, Welsh JB, Cordero TL, et al. Effectiveness of automated insulin management features of the MiniMed® 640G sensor-augmented insulin pump. Diabetes Technol Ther. 2016;18:657–63. This article reports an analysis of real-world usage patterns of MiniMed 640G use and predictive pump suspension. CrossRefPubMedPubMedCentral
62.
• Abraham MB, de Bock M, Paramalingam N, O'Grady MJ, Ly TT, George C, et al. Prevention of insulin-induced hypoglycemia in type 1 diabetes with predictive low glucose management system. Diabetes Technol Ther. 2016;18:436–43. This study examines the effectiveness of predictive low glucose management (PLGM) system in preventing insulin-induced hypoglycemia. CrossRefPubMed
63.
Abraham MB, Davey R, O'Grady MJ, Ly TT, Paramalingam N, Fournier PA, et al. Effectiveness of a predictive algorithm in the prevention of exercise-induced hypoglycemia in type 1 diabetes. Diabetes Technol Ther. 2016;18:543–50.CrossRefPubMed
64.
Danne T, Tsioli C, Kordonouri O, Blaesig S, Remus K, Roy A, et al. The PILGRIM study: in silico modeling of a predictive low glucose management system and feasibility in youth with type 1 diabetes during exercise. Diabetes Technol Ther. 2014;16:338–47.CrossRefPubMed
65.
• Biester T, Kordonouri O, Holder M, Remus K, Kieninger-Baum D, Wadien T, et al. “Let the algorithm do the work”: reduction of hypoglycemia using sensor-augmented pump therapy with predictive insulin suspension [SmartGuard] in pediatric type 1 diabetes patients. Diabetes Technol Ther. 2017;19:173–82. This study examines the effectiveness of predictive low glucose suspend in preventing hypoglycemia in a pediatric population. CrossRefPubMedPubMedCentral
66.
Scaramuzza AE, Arnaldi C, Cherubini V, Piccinno E, Rabbone I, Toni S, et al. Use of the predictive low glucose management (PLGM) algorithm in Italian adolescents with type 1 diabetes: CareLink data download in a real-world setting. Acta Diabetol. 2017;54:317–9.CrossRefPubMed
67.
Fanelli CG, Lucidi P, Bolli GB, Porcellati F. Hypoglycemia. In: Bonora E, DeFronzo R, editors. Diabetes complications, comorbidities and related disorders, Endocrinology. Cham: Springer; 2018. p. 1–38.
68.
Giménez M, Lara M, Conget I. Sustained efficacy of continuous subcutaneous insulin infusion in type 1 diabetes subjects with recurrent non-severe and severe hypoglycemia and hypoglycemia unawareness: a pilot study. Diabetes Technol Ther. 2010;12:517–21.CrossRefPubMed
69.
Yeh HC, Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012;157:336–47.CrossRefPubMed
70.
Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ. 2011;343:d3805.CrossRefPubMedPubMedCentral
71.
Little SA, Leelarathna L, Walkinshaw E, Tan HK, Chapple O, Lubina-Solomon A, et al. Recovery of hypoglycemia awareness in long-standing type 1 diabetes: a multicenter 2 × 2 factorial randomized controlled trial comparing insulin pump with multiple daily injections and continuous with conventional glucose self-monitoring [HypoCOMPaSS]. Diabetes Care. 2014;37:2114–22.CrossRefPubMed
72.
• Little SA, Speight J, Leelarathna L, Walkinshaw E, Tan HK, Bowes A, et al. Sustained reduction in severe hypoglycemia in adults with type 1 diabetes complicated by impaired awareness of hypoglycemia: 2-year follow-up in the HypoCOMPaSS randomized clinical trial. Diabetes Care. 2018; https://​doi.​org/​10.​2337/​dc17-2682. The study highlights the importance of the structured approach, patient education, and follow-up in specialized centers as the determining factor in reducing hypoglycemia and improving the awareness of hypoglycemia, even independent of technology.
73.
Ly TT, Nicholas JA, Retterath A, Lim EM, Davis EA, Jones TW. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial. JAMA. 2013;310:1240–7.CrossRefPubMed
74.
Heinemann L, Hermanns N. IQWiG reanalyzes and raises questions about an article by Ly et al which concluded low glucose suspend is very beneficial. J Diabetes Sci Technol. 2015;10:185–90.CrossRefPubMedPubMedCentral
75.
• van Beers CA, DeVries JH, Kleijer SJ, Smits MM, Geelhoed-Duijvestijn PH, Kramer MH, et al. Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia [IN CONTROL]: a randomised, open-label, crossover trial. Lancet Diabetes Endocrinol. 2016;4:893–902. This trial investigated the use of continuous glucose monitoring (CGM) in patients with type 1 diabetes and impaired awareness of hypoglycaemia. CrossRefPubMed
76.
• Rickels MR, Peleckis AJ, Dalton-Bakes C, Naji JR, Ran NA, Nguyen HL, et al. Continuous glucose Mmonitoring for hypoglycemia avoidance and glucose counterregulation in long-Sstanding type 1 diabetes. J Clin Endocrinol Metab. 2018;103:105–14. This study used real-time CGM as a strategy for prevention of hypoglycemia to assess whether such prevention could improve glucose counterregulation measured by the EGP response to insulin-induced hypoglycemia in patients with long-standing T1D complicated by hypoglycemia unawareness. CrossRefPubMed
77.
• Gómez AM, Marín Carrillo LF, Muñoz Velandia OM, Rondón Sepúlveda MA, Arévalo Correa CM, Mora Garzón E, et al. Long-term efficacy and safety of sensor augmented insulin pump therapy with low-glucose suspend feature in patients with type 1 diabetes. Diabetes Technol Ther. 2017;19:109–14. A study describing the long-term outcomes of SAP therapy with low-glucose suspend feature (SAP+LGS) in hypoglycemia in a Colombian population with T1D and hypoglycemia unawareness. CrossRefPubMed
78.
•• Heinemann L, Freckmann G, Ehrmann D, Faber-Heinemann G, Guerra S, Waldenmaier D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections [HypoDE]: a multicentre, randomised controlled trial. Lancet. 2018;391:1367–77. A trial with potential broad application that has evaluated the effectiveness of RT-CGM in avoidance of hypoglycemia among high-risk individuals with type 1 diabetes in SMBG and treated with MDI. CrossRefPubMed
79.
• Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kröger J, Weitgasser R. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388:2254–63. A trial showing a reduction in the mean time spent in hypoglycemia by using a factory-calibrated, sensor-based, flash glucose-monitoring system compared with self-monitored glucose testing in patients with type 1 diabetes. CrossRefPubMed
80.
Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8:55–73.CrossRefPubMed
81.
• Beck RW, Riddlesworth TD, Ruedy K, Ahmann A, Haller S, Kruger D, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167:365–74. A 24-week randomized trial comparing the effectiveness of CGM in adults with type 2 diabetes receiving multiple daily injections of insulin. CrossRefPubMed
82.
Gehlaut RR, Dogbey GY, Schwartz FL, Marling CR, Shubrook JH. Hypoglycemia in type 2 diabetes--more common than you think: a continuous glucose monitoring study. J Diabetes Sci Technol. 2015;9:999–1005.CrossRefPubMedPubMedCentral
83.
Pazos-Couselo M, García-López JM, González-Rodríguez M, Gude F, Mayán-Santos JM, Rodríguez-Segade S, et al. High incidence of hypoglycemia in stable insulin-treated type 2 diabetes mellitus: continuous glucose monitoring vs. self-monitored blood glucose. Observational prospective study. Can J Diabetes. 2015;39:428–33.CrossRefPubMed
84.
Russell SJ, El-Khatib FH, Sinha M, Magyar KL, McKeon K, Goergen LG, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med. 2014;371:313–25.CrossRefPubMedPubMedCentral
85.
Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5:501–12.CrossRefPubMed
86.
Russell SJ, Hillard MA, Balliro C, Magyar KL, Selagamsetty R, Sinha M, et al. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Lancet Diabetes Endocrinol. 2016;4:233–43.CrossRefPubMedPubMedCentral
87.
• Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017;19:155–63. A trial evaluating in-home use of the Medtronic MiniMed® 670G hybrid closed-loop insulin delivery system over 3 months in both adolescents and adults with type 1 diabetes. None of the participants experienced a severe hypoglycemic or diabetic ketoacidosis, demonstrating the safety of the system. CrossRefPubMedPubMedCentral
88.
McAuley SA, de Bock MI, Sundararajan V, Lee MH, Paldus B, Ambler GR, et al. Effect of 6 months of hybrid closed-loop insulin delivery in adults with type 1 diabetes: a randomised controlled trial protocol. BMJ Open. 2018;8:e020274.PubMedPubMedCentral

Be confident that your patient care is up to date

Medicine Matters is being incorporated into Springer Medicine, our new medical education platform. 

Alongside the news coverage and expert commentary you have come to expect from Medicine Matters diabetes, Springer Medicine's complimentary membership also provides access to articles from renowned journals and a broad range of Continuing Medical Education programs. Create your free account »